Pharmaceuticals company GlaxoSmithKline Pharmaceuticals announced Q1FY26 results Revenue from Operations stood at Rs 805 crore. Profit After Tax (PAT) of Rs 205 crore. Bhushan Akshikar, Managing Director, GlaxoSmithKline Pharmaceuticals, said: “GSK continues to invest in its innovative portfolio and is on track to launch the much-awaited oncology assets, Jemperli and Zejula. By launching these assets in India, GSK is addressing a critical unmet need amid a rising cancer burden and limited access to advanced therapies.” Jemperli (dostarlimab) is an immuno-oncology treatment for second-line dMMR endometrial cancer and Zejula (niraparib), is a PARP inhibitor indicated for advanced and recurrent ovarian cancer. Result PDF